Biliary Tract Cancer New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers Ulas D. Bayraktar, MD 2023-11-20
Prostate Cancer New Reference: Enzalutamide in Recurrent Prostate Cancer Ulas D. Bayraktar, MD 2023-11-20
GastroEsophageal Cancer New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer Ulas D. Bayraktar, MD 2023-11-20
GastroEsophageal Cancer New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer Ulas D. Bayraktar, MD 2023-11-20
Multiple Myeloma New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma Ulas D. Bayraktar, MD 2023-11-20
Colorectal Cancer New Indication: Sotorasib with Panitumumab in kRAS G12C Mutated Colorectal Cancer Ulas D. Bayraktar, MD 2023-11-20
Mesothelioma New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma Ulas D. Bayraktar, MD 2023-11-20
Colorectal Cancer New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer Ulas D. Bayraktar, MD 2023-09-23
Soft Tissue Sarcoma New Indication: Atezolizumab for Advanced Alveolar Soft Part Sarcoma Ulas D. Bayraktar, MD 2023-09-23
